Three-year assessment of the counselling cannabis clinics for young users (2005-2007)
Tendances n° 63, OFDT, 4 p.
Cannabis is the most widely used illegal substance in France, particularly in young people, despite a fall in use since 2002 after ten years of continuous increase. In 2007, 5% of 16-year-old males and 2% of 16-year-old females reported that they used cannabis regularly.
Three years after the introduction of the "clinics for young users" (CYU) and following an initial survey, this work reviews the change in the outpatients' profiles (see box) based on the responses of professionals who managed the outpatients in 226 of the 274 CYU identified in 2007 (or 82%). The analyses are based on a sample of 3,788 people, of whom 2,938 were substance users (77.6% of the public in a given month), 79% of whom attended alone, and 850 people from the person's family or close friends (22.4%). These allow the new trends and features of the public seen to be identified by recruitment sector. The results presented include previously unpublished findings about the nature of the requests, the reasons for use, criteria used to assess dependency, responses offered to the different user profiles and the change in their use trajectory during the sessions.
Download the PDF file (116 Ko)
Drugs in Europe
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
What do the latest data tell us about drug production and trafficking trends?
These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.